Last updated on September 2016

A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations


Brief description of study

A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations

Detailed Study Description

The objective of this study is to describe the occurrence of AEs leading to dose reduction following afatinib treatment in NSCLC patients with common EGFR mutations (Deletion 19 and/or L858R) who are 70 years of age or older.

Clinical Study Identifier: TX145454

Find a site near you

Start Over

Clinical Trials and Research Associates, Inc

120 West Beverly Blvd Montebello, CA USA
8.05miles
  Connect »

Los Angeles Hematology Oncology Medical Group

1245 Wilshire Blvd Suite 303 Los Angeles, CA USA
9.24miles
  Connect »